Value Sense
LEGN
Legend Biotech Corporation (LEGN)
Last Price$37.29.3%
Market Cap$3,309.7M
LTM P/E
(9.5x)
EPS growth
(60.6%)
PEGY
0.2x
Peter Lynch Fair Value
$237.2
Undervalued (Peter Lynch formula)
537.7%
Stock quality
6/10
Good
LEGN
is 83.7% undervalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

LEGN Peter Lynch Fair Value

Peter Lynch Fair Value Assumptions

as of Mar 12, 2025
LTM P/E
(9.5x)
EPS growth
(60.6%)
Dividend Yield
0.0%
PEGY
0.2x
Last share price
$37.2
Peter Lynch Fair Value
$237.2
537.7% undervalued

Peter Lynch Fair Value Calculation

PEGY
0.2x
=
LTM P/E
(9.5x)
/
(
EPS growth
(60.63%)
+
Dividend yield
0.00%
)
Peter Lynch
Fair Value
$237.2
=
Last share price
$37.2
/
PEGY
0.2x

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

LEGN EPS growth & Dividend Yield

Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
EPS growth
Dividend Yield

LEGN vs Peer Set: Peter Lynch Fair Value Comparison

General

PETER LYNCH FAIR VALUE

Financial metrics

Company name

Undervaluation / Overvaluation

Revenue growth

EBITDA margin

Net Income margin

Legend Biotech Corporation logo
Legend Biotech CorporationLEGN
537.7%
143.7%
4.6%
(181.8%)
Median Peer Set
18.0%
(38.6%)
15.0%
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
12,147.4%
73.7%
467.1%
(35.9%)
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
(64.6%)
8.3%
10.4%
31.1%
Royalty Pharma plc logo
Royalty Pharma plcRPRX
300.3%
(3.8%)
(43.7%)
37.9%
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
(59.6%)
23.6%
25.7%
41.5%
BioMarin Pharmaceutical Inc. logo
BioMarin Pharmaceutical Inc.BMRN
23.9%
18.0%
139.3%
15.0%
Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
(145.4%)
N/A
(68.7%)
N/A
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
N/A
11.7%
N/A
(4.9%)
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
N/A
23.0%
(38.6%)
(12.4%)
argenx SE logo
argenx SEARGX
N/A
198.6%
(60.5%)
(24.1%)
BioNTech SE logo
BioNTech SEBNTX
N/A
(77.4%)
(89.7%)
24.4%

Explore more intrinsic value tools hub for LEGN

Margin of safety
Ben Graham Fair Value
Earnings growth model
Discount rate
Peter Lynch charts
Reverse DCF
Earnings Power Value
Intrinsic Value
DCF value calculator
Relative Value

FAQ

What is Legend Biotech Corporation fair value by Peter Lynch formula?

As of Mar 11, 2025, Legend Biotech Corporation's fair value using the Peter Lynch formula is $237.2 per share. The current price of $37.2 suggests Legend Biotech Corporation may be undervalued by this metric.

What is Legend Biotech Corporation Price to Earnings (P/E) ratio?

As of Mar 11, 2025, Legend Biotech Corporation's P/E ratio is (9.5x). This is calculated by dividing the current share price of $37.2 by the Earnings per Share (EPS) for the trailing twelve months, which is ($1.2). The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.

What is Legend Biotech Corporation earnings per share (EPS)?

Legend Biotech Corporation earnings per share (EPS) for the twelve months ending Mar 11, 2025, was ($1.2), a (60.6%) growth year-over-year.